Rosa to Provide Noncompartmental Pharmacokinetic Analyses (NCAs) for Advanced Research Institute

Nov. 14, 2011 - PRLog -- Advanced Research Associates, Inc. (ARA) and Rosa & Co. LLC jointly announced today an alliance that will provide Rosa’s noncompartmental pharmacokinetic analysis (NCA) capability to ARA customers as part of ARA’s seamless data management and biostatistics offering.

“ARA’s partnership with Rosa allows us to bolster our already comprehensive data management and biostatistical services with the benefits of Rosa’s PK/PD analysis and modeling technology. We are now able to provide the full range of statistical analysis services to our many clients in the biotech, pharmaceutical, and medical device industries,” said Peter Shabe, ARA President. “This valuable partnership offers a more streamlined approach to clinical trials management. Working together, ARA and Rosa will cover all the requirements of a clinical trial, including data management, biostatistics, and pharmacokinetic and pharmacodynamic analyses, with the personalized, flexible, study-specific approach that makes them industry leaders.”

“Combining our NCA and clinical pharmacology expertise with ARA’s data management and biostatistics expertise is a natural way to provide seamless data management and analysis.” said Ron Beaver, Ph.D., CEO, and Founder of Rosa. “Together, we can deliver faster drug development and greater scientific insight to ARA’s customers.”

About ARA
ARA is an industry-leading Clinical Research Organization (CRO) based in Mountain View, CA, focusing on providing data management and biostatistical contract and consulting services. Over the past 15 years, ARA has become a trusted partner with over 300 companies in the biotech, pharmaceutical and medical device industries. Therapeutic areas that ARA has supported include cardiovascular, endocrinology, dermatology, oncology, pulmonary, and infectious diseases, among others.

ARA has provided a spectrum of innovative solutions and has lent its data management and biostatistical expertise across a wide range of projects.  While these customized solutions are based on clients’ needs and requirements, the success of any project hinges on the strength of the relationship developed through constant communication and a collaborative approach to getting the work done. As a result, ARA’s clients consistently achieve their highest objectives. For more information, please visit www.advanceresearch.com.

For further information please contact:
Advance Research Associates
650-810-1190

About Rosa
Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have close to two decades of unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development; they have covered hundreds of applications with dozens of clients. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.

Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.

For further information please contact:
Rosa & Co
408-370-9800

# # #

Rosa creates robust mathematical models that simulate drug effects and trial outcomes. Modeling and Simulation complement traditional experimental methods, enabling unique insights that streamline drug development and regulatory interactions.